Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Pyrimidines. Found 26 abstracts

no pagination
Chien CR, Geynisman DM, Kim B, Xu Y, Shih YT. Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review. PharmacoEconomics. 2019 Mar;37(3):301-31.   PMCID: PMC6886358
Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DY, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer. 2018 Oct 22;6(1):109.   PMCID: PMC6196426
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DP, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine. 2018 Feb 22;378(8):731-9.   PMCID: PMC5857389
Prudnikova TY, Chernoff J. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases. 2017 Oct 02;8(4):193-8.   PMCID: PMC5680705
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan;22(1):34-43.
Gritsina G, Xiao F, O'Brien SW, Gabbasov R, Maglaty MA, Xu RH, Thapa RJ, Zhou Y, Nicolas E, Litwin S, Balachandran S, Sigal LJ, Huszar D, Connolly DC. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth. Mol Cancer Ther. 2015 Apr;14(4):1035-47.   PMCID: PMC4394029
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, El-Deiry WS. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther. 2015 Jan;16(12):1710-9.   PMCID: PMC4847811
Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene. 2012 Mar 08;31(10):1217-27.   PMCID: PMC3204164
von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?. Cancer Treat Rev. 2011 Jun;37(4):291-9.   PMCID: not NIH funded
von Mehren M, Watson JC. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?. Oncology (Williston Park). 2009 Jan;23(1):65-6.   PMCID: PMC 2861343
Belinsky MG, Rink L, Cai KQ, Ochs MF, Eisenberg B, Huang M, von Mehren M, Godwin AK. The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell cycle (Georgetown, Tex). 2008 Oct;7(19):2949-55.   PMCID: PMC2626174
Makhov P, Golovine K, Uzzo RG, Rothman J, Crispen PL, Shaw T, Scoll BJ, Kolenko VM. Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Cell death and differentiation. 2008 Nov;15(11):1745-51.   PMCID: PMC2585550
Patel BB, He YA, Li XM, Frolov A, Vanderveer L, Slater C, Schilder RJ, von Mehren M, Godwin AK, Yeung AT. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics. 2008 May;5(3-4):137-49.
Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92.   PMCID: PMC2448846
Tarn C, Godwin AK. The molecular pathogenesis of gastrointestinal stromal tumors . Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S7-17.
Turner DP, Cortellino S, Schupp JE, Caretti E, Loh T, Kinsella TJ, Bellacosa A. The DNA N-glycosylase MED1 exhibits preference for halogenated pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine. Cancer Res. 2006 Aug;66(15):7686-93.
von Mehren M. Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies. Current oncology reports. 2006 May;8(3):192-7.
Dushkin H, Schilder RJ. Imatinib mesylate and its potential implications for gynecologic cancers. Current treatment options in oncology. 2005 Mar;6(2):115-20.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Pyrimidines

Pyrimidines pharmacology drug therapy genetics therapeutic use Antineoplastic Agents Female pathology antagonists & inhibitors Piperazines metabolism Tumor Cell Line Gastrointestinal Stromal Tumors Pyrroles Male drug effects Protein Kinase Inhibitors Signal Transduction Treatment Outcome Sulfonamides Kidney Neoplasms Middle Aged Neoplasm Metastasis Ovarian Neoplasms Apoptosis Renal Cell Carcinoma Adult administration & dosage Neoplasm Drug Resistance Indoles Pyrazoles methods therapy enzymology Aged diagnosis Drug Administration Schedule Antineoplastic Combined Chemotherapy Protocols Mice Nephrectomy Gene Silencing Protein-Tyrosine Kinases chemistry Organ Sparing Treatments Mutation Proto-Oncogene Proteins c-akt Gene Expression Profiling Drug Monitoring Disease Progression Platelet-Derived Growth Factor alpha Receptor Nephrons Small Interfering RNA Maximum Tolerated Dose Angiogenesis Inhibitors Retreatment Neoplastic Gene Expression Regulation Carcinogenesis Cell Proliferation Proto-Oncogene Proteins c-kit Local Neoplasm Recurrence src-Family Kinases Lymphoma Zinc X-Ray Computed Tomography Acetophenones Janus Kinases ovarian cancer 152459-95-5 (imatinib) Immune checkpoint inhibitor Human Chromosomes-Pair 11 Enzyme Activation Sunitinib Endodeoxyribonucleases protein kinase oncogene mo [Mortality] Gene Amplification Survival Analysis blood surgery Drug Delivery Systems 80 and over Aged Phenylurea Compounds Chelating Agents IGF Type 1 Receptor Preschool Child Nivolumab Cell Line Cost of Illness Infant Integrin alphaVbeta3 capecitabine Clinical Trials as Topic chromosomal amplification Positron-Emission Tomography Metastatic renal cell carcinoma Tumor Biomarkers Piperidines Animal Disease Models Cell Adhesion deficiency Pazopanib Prostatic Neoplasms Young Adult Biological Models Ethylamines Biological Availability Phosphorylation metastatic colorectal adenocarcinoma Cell Survival Sulfones Prognosis Adolescent 0 (Piperazines) Protease Inhibitors Mass Spectrometry Fluorouracil DNA Mutational Analysis Thiazoles CpG Islands 5-fu Idoxuridine pc [Prevention & Control] regorafenib Platelet-Derived Growth Factor Receptors Biomarkers economics pk [Pharmacokinetics] physiology Intracellular Space Drug Dose-Response Relationship inhibitors Biopsy Proteasome Endopeptidase Complex Molecular Targeted Therapy Cluster Analysis Matrix Metalloproteinases Drug Synergism Base Pair Mismatch Antiangiogenic pharmacokinetics X-Linked Inhibitor of Apoptosis Protein 0 (Pyrimidines) Vascular Endothelial Growth Factor Receptors Disease-Free Survival Benzopyrans secondary STAT3 Transcription Factor trends Caspases
Last updated on Wednesday, August 12, 2020